fda drug safety communication naion semaglutide 2025 Suboptimal therapeutic responses associated with in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials: Cell Reports Medicine fda drug safety communication naion

(PubMed) Donadio JV, Grande JP

In much the same way that your body needs consistent replenishment of food and water, it needs Vitamin C to survive and thrive

Excited to share our latest publication in Innovative Food Science and Emerging Technologies: Antioxidant assessment of a glutathione-rich extract obtained from electroporated cells of Saccharomyces cerevisiae in white grape must In this work, we explored a natural and sustainable alternative to reduce sulfite use in winemaking

Results from the SELECT trial also indicated that a dose of 2.4mg of semaglutide has potential to combat kidney function decline among individuals with cardiovascular disease who are overweight or have obesity, but without diabetes